(infliximab and adalimumab ADA ). These TNF blockers act by inhibiting the binding of TNFs to TNF receptors on the cell surface and [ ] therefore interfere with TNF-driven signal transduction pathways. Etanercept binds to both TNF and TNF (or lymphotoxine LTA )
and infliximab and adalimumab to TNF only. TNF blockers are efficient in about 70 of patients, but 30 are resistant.
Taking into account the cost of these treatments in RA, the persisting questions about potential long-term adverse events (infections and cancers) and the availability of other efficient biotherapies, the identification of predictive factors of response to treatment is a key issue. In this field, pharmacogenetic approaches give promising hope. Nevertheless, few studies have been performed to date and some have led to contradictory results, especially those concerning the role of the shared epitope (SE) and/or -308A/G polymorphism TNF [1-12 ( ). ] Table 1 The aim of this study was to determine whether the SE and/or gene polymorphisms, analyzed separately or after haplotype TNFα reconstruction, are genetic predictors of response to ADA in patients with RA.
METHODS

Patients
This pharmacogenetic study was ancillary to the Research in Active Rheumatoid Arthritis (ReAct) protocol performed at various sites in Europe and Australia. In the parent ReAct study, 6610 patients were included to assess the safety and effectiveness of ADA, a fully human IgG anti-TNF monoclonal antibody. The objectives of the ReAct study were to evaluate patients for efficacy and tolerance of 1 ADA in combination with a variety of disease-modifying antirheumatic drugs (DMARDs), including those previously treated with etanercept or infliximab. Briefly, patients enrolled in the ReAct study were men and women 18 years of age with active, adult-onset RA ≥ as defined by the 1987 revised criteria of the American College of Rheumatology (ACR) . Inclusion criteria required a disease duration [13] 3 months; a disease activity score based on erythrocyte sedimentation rate and an evaluation of 28 joints (DAS28) 3.2, indicating at
least moderate disease activity; and failure of treatment with at least 1 traditional DMARD. Previous therapy with biologic response modifiers including other TNF antagonists was allowed if the medication was discontinued at least 2 months before enrolment.
The pharmacogenetic study we describe here concerns a large cohort of 398 French patients included in the ReAct study. All the patients provided written informed consent. The study was approved by the local ethics committee. Eight patients were excluded owing to their Asian or African descent ( ). Ten other patients were excluded from the main statistical analysis because of missing ACR50 Figure 1 response data at 12 weeks. Thus, 380 patients from the original population were eligible for the study and underwent treatment with ADA plus MTX (n 182), ADA plus any other DMARD (n 96) or ADA alone (n 102).
Collection of clinical and biological data and outcome measures
The clinical and biological data were from the original ReAct protocol. At baseline and weeks 2, 6, and 12, scores for variables necessary to assess DAS 28 and ACR response were recorded, as were scores on the Health Assessment Questionnaire-Disability Index (HAQ). Outcomes were measured after 12 weeks of treatment. The primary outcome for the genetic study was ACR50 response, secondary outcomes were ACR20 and ACR70 responses. TNF TNF+ three studied SNPs encompasse the entire TNF promoter locus, leading hence, as expected, to obtain the four main haplotypes cited below in our Caucasian population of RA patients.
Genetic polymorphisms in and HLA genes TNF
Because definite HLA-DRB1 alleles have been previously reported to play an important role in RA susceptibility --the SE hypothesis --and severity , we genotyped our RA patients for HLA-DRB1 alleles by direct sequencing. The alleles considered to have the SE [17] [ 18] were HLA-DRB1 0101, 0102, 0401, 0404, 0405, 0408, 0413, 1001, and 1402 . To analyze the SE contribution in response to 3 11 TNF 238A/G PCR gene polymorphisms was genotyped by mismatch polymerase chain reaction (PCR) -restriction fragment full -length polymorphism (RFLP) using the MspI restriction enzyme. Primers used for PCR amplification were: forward 5′ ATCTGGAGGAAGCGGTAGTG3 and reverse 5 AGAAGACCCCCCTCGGAACC3 . Forward primer contained a purposeful 3 ′ ′ ′ ′ mismatch, so that when incorporated into the PCR products they create a MspI restriction site with the G allele but not with the A allele.
-308A/G polymorphism was genotyped by allelic discriminating TaqMan PCR by use of the PreDeveloped TaqMan 
Statistical analysis
All quantitative data are expressed as the mean / SD and all qualitative data as frequencies and percentages. All genotyped SNPs The factors influencing the probability of achieving an ACR50 response at week 12 were studied through multivariate logistic regression. In addition to the SNPs and to the haplotypes described above, we considered the following covariates: gender, age, weight, clinical variables measured at baseline, duration of disease, presence of rheumatoid factor (RF) and concomitant treatment. First, univariate logistic regressions were performed to screen covariates. The models with and without a given covariate were compared using a log-likelihood ratio test, that is, by comparing twice the difference in log-likelihoods of the two model to the critical values of the χ 2 statistic. We kept all the covariates for which the p-value of this test was less than 0.15. A multivariate regression model was then built including all candidate covariates selected in the previous step, and the final model was selected through backward selection, using log-likelihood ratio tests as previously. At this stage, covariates were kept in the model if the p-value of the test was less than 0.05.
RESULTS
Description of the cohort
The baseline characteristics of patients are presented in . The profile of clinical response of the 380 patients included in this Table 2 pharmacogenetic study was the same as that of the entire ReAct population (6610 patients). At 12 weeks, 40 of the patients (n 151)
showed an ACR50 response, 71 (n 263) an ACR20 response and 16 (n 59) an ACR70 response. MTX adjunction to ADA therapy
was significantly associated with a better ACR50 response both in univariate (P 0.005) and multivariate analyses (odds ratio OR , 1.68;
95 confidence interval CI , 1.07 2.66; 0.026). In the subgroup of patients not receiving methotrexate, there was a non significant
P= trend for a better response when other DMARDs were administered in addition to ADA (38 of ACR50 responders versus 29 in patients % %
given only ADA, NS).
Genotype distributions were as follows: for -238 G>A (N 364), 94 GG, 5 AG, and one patient had the rare AA genotype; for TNF = % % -308 G>A (N 373), 71 GG, 26 AG, and 3 had the AA genotype; for -857 C>T (N 361), 82.7 CC, 17 CT, and one TNF = % % % TNF = % % patient had the rare TT genotype. These distributions were consistent with data from public databases for Caucasians ( ). http://www.ncbi.nlm.nih.gov/projects/SNP SE could be determined in 326 patients. The distribution of the SE among patients was as follows: 25.4 had no copies, 47.6 1 % % copy, and 27 2 copies, for a total of 74.6 carriers.
% %
In 346 patients in whom we determined the 3 SNPs of the promoter (-238A/G, -308A/G and -857C/T), we identified four main TNFα haplotypes (e.g., the haplotype GGC consisted of -238G, -308G and -857C). These most frequent haplotypes (GGC, GAC, GGT and AGC) accounted for more than 99 of the total number of haplotypes, with frequencies of occurrence of 74 , 14 , 8 and 3 , % % % % % respectively. The rare AAC haplotype was found in only one patient.
Univariate and multivariate analysis of factors influencing ACR50 response to ADA
We used binary logistic regression to study the probability of achieving the ACR50 response to ADA therapy at 12 weeks. Univariate regression to screen for variables (with P < 0. 
P=
Influence of the SE and individual genotypes on ADA response TNFα
The SE was not identified in uni-or multivariate analysis as a factor influencing ACR50 response to ADA therapy at week 12. In fact, we found no association between ACR50 response to ADA and SE copy number or carrier status ( ) or any of the 3 Figure 2A and 2B TNFα gene polymorphisms -238A/G, -308A/G and -857C/T genotypes ( ) tested individually. However, we found a trend of Figure 2C , 2D and 2E
an association between a lower response to ADA therapy at 12 weeks and -238GG, -308GG and -857CC genotypes ( Figure 2C, 2D and 2E ).
Influence of the haplotype on ADA response TNFα
In analyzing the influence of haplotype on response to ADA therapy, GGC haplotype carrier status showed significant results ( TNFα ). In the first analysis, we discarded rare haplotype combinations (N 27) represented fewer than 10 times: AGC/AAC (N 1), Figure 3A ). This observation highly suggested a recessive effect of the GGC haplotype on response to treatment. In P= P c = Figure 3A fact, the response rate for homozygous GGC haplotype carriers (34 ; N 184) was significantly lower than the response rate observed ). Figure 3B A similar but non significant trend was observed for ACR20 and ACR70 responses to ADA therapy at week 12: The GGC/GGC group showed a 69 ACR20 response versus 76 for the other haplotype carriers (P 0.14) and a 15 ACR70 response versus 19 for the other % % = % % haplotype carriers (P 0.3). The lack of significant difference regarding ACR20 and ACR70 responses can be explained by a lack of = statistical power since responders and non responders are unbalanced with these criteria. Conversely, ACR50 response at week 12 provides the best statistical power to demonstrate an effect with a distribution of responders and nonresponders approaching 50 of the whole % population.
As well as our finding of the homozygous effect of the GGC haplotype, we noted a trans effect of certain haplotypes present on the " " opposite chromosome. Alone, the trans association of the AGC haplotype with the GGC haplotype appeared to be associated with a including the rare ones. The difference between those groups was not significant after Bonferroni correction (P 0.019; Pc 0.095).
= =
Nevertheless, few patients were AGT haplotype carriers (10 ACR50 responders and 4 ACR50 nonresponders), so this analysis was therefore underpowered.
Baseline characteristics did not significantly differ between GGC homozygous patients and other haplotype carriers, especially in DAS28 RA disease-activity criteria ( ). Table 2 Since about half of our sample received MTX therapy with ADA, we further analyzed the GGC homozygosity effect according to treatment: ADA plus MTX, ADA plus any other DMARD, and ADA alone. Surprisingly, the lower ACR50 response rate was present mainly in the group of patients receiving ADA plus MTX (n 182): 38 ACR50 response versus 60 for the other haplotype carriers (P = % % = Page / 5 11 0.006; 0.03) ( ). For the ADA plus other DMARD group (n 96), we observed a similar, although not significant, trend: 32 P c = Figure 3C = % ACR50 response versus 48 for the other haplotype carriers ( ). For the ADA-alone group (n 102), the GGC homozygous % Figure 3C = haplotype had no significant effect (29 versus 32 for the other haplotype carriers) ( ).
% % Figure 3C In analyzing the time-course evolution of ACR50 response among treatment groups, for patients receiving ADA plus MTX, the response differed between GGC haplotype homozygous and other haplotype carriers as soon as week 2 after treatment initiation and increased until week 12 ( ). For patients receiving ADA plus any other DMARD, the response showed a trend in favor of a Figure 4A difference between haplotype groups over time, which might have become significant with longer follow-up, which was not available in the ReAct protocol ( ). For patients receiving ADA alone, the response did not significantly differ between haplotype groups over Figure 4B 
time (
). Figure 4C Influence of the SE on the negative effect of GGC homozygosity on ADA response
The locus is located near , so we analyzed the extent to which the GGC haplotype was in LD with the SE. Although TNFα HLA DRB1
some alleles belonging to the SE were in LD with the some TNF gene alleles, the overall LD between the GGC haplotype and the SE alleles was weak, with a Somers D equal to 0.24.
′
Our extended haplotype reconstructions resulted in 82 SEhaplotype combinations. Careful examination of these haplotypes TNF showed the GGC haplotype mainly associated with HLA DRB1 0101 and 0401 alleles of the SE, which is not surprising because GGC is 
DISCUSSION
This large pharmacogenetic study has investigated the effect of gene polymorphisms on response to ADA in RA patients. TNFα
Although the presence of individual SNPs was not associated with a specific pattern of response to ADA, haplotype analysis TNFα provided convincing data suggesting that the ancestral haplotype of the promoter, GGC, the most frequent among Caucasians , TNFα [15] was associated with a lower response to ADA when present in the homozygous form.
Pharmacogenetic studies of the influence of genes on response to TNF blocker treatment in RA have given discordant results ( TNF ). Two studies reported an association of the A-308GG genotype with better response to infliximab or etanercept but Table 1 TNF
concerned only a limited number of patients: 59 and 22, respectively. A recent study suggested that the A -308GG genotype was TNF associated with a better response to TNF blockers (ADA, infliximab or etanercept) at week 24, independent of rheumatic disease (i.e., RA, psoriatic arthritis or ankylosing spondylitis)
. Again, this study involved a limited number of patients (N 88), of whom only 54 had
RA. Studies involving larger sample sizes N 151 with etanercept (2) and N 198 with infliximab (11) did not confirm these results, nor
did ours, with 381 patients receiving ADA therapy. A study of 70 Asian patients did not find any association of -308A/G with TNF response to etanercept . [9] Many explanations may account for such discrepancies, but the small number (less than 80 patients) of subjects in the positive studies is the best probable explanation, since the 3 negative studies each included more than 150 patients. Moreover, parameters such as the response criteria chosen as primary endpoint (DAS28 decrease, ACR20 or ACR50 response) and the delay of efficacy for the primary endpoint (range from 6 to 24 months from baseline) differed among studies , , , , . [2 4 7 8 12] Interestingly, few of these studies focused on haplotypes as a factor that could influence response to TNF blockers. One study TNF analyzed extended haplotypes comprising HLA DRB1 alleles, 488/-238/-308 polymorphisms and lymphotoxin 720/365/249 TNFα α polymorphisms. This study involved a US Caucasian population and reported an association of 2 extended haplotypes with better response to etanercept in RA . Unfortunately, the authors did not analyze the effect of polymorphism haplotypes alone on response to [2] TNFα etanercept, which precluded any comparison with our results. Another study analyzing the effect of haplotypes on response to TNF TNFα blockers involved an Asian population . The different ethnic origin of the patients in this last report limits a comparison with our results. [9] Nevertheless, extended haplotypes were inferred from five promoter polymorphisms ( 1031, 863, 857, 308, 238). The TNFα
frequency of haplotypes carrying -238G, -308G, and -857C alleles was 71 in the Asian population, very close to the 73 observed in our % % Caucasian population, which suggests a similar frequency of the (-238G, -308G, and -857C) haplotype in both Caucasian and Asian TNF populations. A haplotypic effect on etanercept response was not evidenced in this study, but no study has investigated a homozygous TNF effect of the main haplotypes with this treatment. Interestingly, patients homozygous for the -857C-allele were poor responders to 6 11 etanercept. In fact, when ACR20 nonresponders were compared with ACR70 responders, the proportion of responders was higher in the TT-CT group than in the CC group (OR, 12; 95 CI, 1.2 120; P 0.033). The result was not significant after Bonferroni correction, but the % -= sample size studied was low (N 70 patients). The result mirrored in part the effect of the (-238G, -308G, and -857C) homozygous = haplotype associated with the lower response to ADA we observed.
The functional effect of promoter haplotypes has not been reported to date. In fact, most of the functional studies of the TNFα TNFα promoter focused on separate analysis of SNPs and mainly on the -308A/G polymorphism. Most published studies reported high TNFα production, among various cell types and stimulation conditions, in the A allele carriers . These results, even if not confirmed by [21] [22] [23] [24] others , are mainly accepted by the scientific community. We found that the (-238G, -308G, and -857C) homozygous [25] [26] [27] TNF haplotype was associated with a lower response to ADA therapy than were other haplotypes. In agreement with a high TNF production α with presence of -308A alleles, poorer responders might be those who produce low levels of TNF . In fact, recent studies suggest that α subjects with high response to TNF blockers could also have high TNF bioactivity or high TNF synovial levels at baseline .
The effect of the (-238G, -308G, and -857C) homozygous haplotype on ADA response was restricted to patients also receiving TNF MTX, with a trend to association with ADA plus any other DMARD treatment, and was absent in patients receiving ADA alone. The reason for such observation remains unclear. A specific effect of promoter polymorphisms on response to MTX itself cannot be TNF excluded. This point has never been addressed before in the literature. MTX plus ADA provided significantly higher response than ADA alone. Such results are markedly enhanced in GGC haplotype homozygous carriers and could help physicians in treatment management. In fact, the necessity for MTX treatment with ADA therapy appears critical in GGC haplotype homozygous carriers, to reach a good ACR50 response rate at week 12.
Discrepancies among published results involve the implication of the SE in response to TNF blockers in RA ( ). One study Table 1 reported increased response to etancercept in patients with 2 copies of the SE (OR, 4.3; 95 CI, 1.8 10.3) (N 151) and a second did
not replicate such results on a larger studied population (N 198) . Regardless, our results among 322 patients do not show any effect of
SE copy number on response to ADA.
In conclusion, this pharmacogenetic study is remarkable because of the size of the population studied as well as the quality of the clinical data recorded within the ReAct study. It provides robust data indicating that a single locus haplotype (-238G/-308G/-857C), TNFα when carried on both chromosomes, is associated with a lower response to ADA in RA patients treated with a combination of ADA and MTX than patients with other haplotypes. The mechanism of action of this genetic predisposition (a specific effect on response to MTX itself or an effect on TNF bioactivity and/or TNF serum levels) needs further investigations. 
